Diagnostics & surveillance research
Active Awarded Last action
- Contract number
- N0018924FZA25
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Naval Supply Systems Command
Department of the Navy, Department of Defense
- Obligated
- $3,025,354
Award facts
- Opportunity
-
- N0018924QZ236 Solicitation number
- Contract value 15% obligated
-
- $10,071,240.03 Current, with exercised options
- $19,838,203.29 Potential, with all options
- Completion date 40% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- Funding agency
- Bureau of Medicine and Surgery Department of the Navy, Department of Defense
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Reston, VA 20190, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $294,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $261,344 | |
| Funding Only Action | $0 | |
| Exercise an Option | $1,299,362 | |
| Original award | $1,170,648 |
About this award
The Department of the Navy Bureau of Medicine and Surgery issued a delivery order to Leidos, Inc. on September 29, 2024, under the Omnibus IV Military Medical Research and Development IDIQ for diagnostics and surveillance research support, with a ceiling value of $19.84 million and ultimate completion date of December 31, 2029.
Omnibus IV is an indefinite delivery contract vehicle supporting military medical research and development across the Defense Health Agency and subordinate commands. Place of performance is Reston, Virginia. The order is priced on a cost-plus-fixed-fee basis.
Leidos is performing diagnostics and surveillance research operations through its Leidos Services Operating Segment. Bio-Rad Laboratories, Inc., a life science manufacturer, is providing diagnostics and surveillance research equipment and consumables as a subcontractor, with documented procurements between June 25 and July 16, 2025. The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., a non-profit military medical research organization, is supporting infectious disease research and related activities as a second subcontractor, with documented performance between September 29, 2024, and June 30, 2025.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Bio-Rad Laboratories, Inc. | $47,769 | |
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | $220,598 |
Quick answers
Who was awarded contract N0018924FZA25?
N0018924FZA25 was awarded to Leidos, Inc. by Naval Supply Systems Command (Department of the Navy) on September 29, 2024.
How much is contract N0018924FZA25 worth?
The government has obligated $3,025,354 on N0018924FZA25. Its current value, with exercised options, is $10,071,240. Its potential value, with all options, is $19,838,203.
Which agency awarded contract N0018924FZA25?
Naval Supply Systems Command (Department of the Navy) awarded N0018924FZA25, with funding from Bureau of Medicine and Surgery (Department of the Navy).
Is contract N0018924FZA25 an order under another contract?
Yes. N0018924FZA25 is a delivery order under HT001122D0028, an indefinite delivery contract, on Omnibus IV Military Medical Research And Development (OMNIBUS IV).
Was contract N0018924FZA25 competed?
The extent of competition for N0018924FZA25 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award